Recombinant Protein Expression in Mammalian Cells Methods and Protoc

This detailed volume explores advances in vector design, DNA delivery, cell cultivation, host cell engineering, and bioprocess optimization within the study of recombinant protein expression in mammalian cells. The majority of the protocols employ ei

  • PDF / 8,716,872 Bytes
  • 311 Pages / 504.63 x 737.01 pts Page_size
  • 79 Downloads / 197 Views

DOWNLOAD

REPORT


David L. Hacker Editor

Recombinant Protein Expression in Mammalian Cells Methods and Protocols

METHODS

IN

MOLECULAR BIOLOGY

Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes: http://www.springer.com/series/7651

Recombinant Protein Expression in Mammalian Cells Methods and Protocols

Edited by

David L. Hacker Protein Production and Structure Core Facility (PPSCF), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

Editor David L. Hacker Protein Production and Structure Core Facility (PPSCF) Ecole Polytechnique Fe´de´rale de Lausanne (EPFL) Lausanne, Switzerland

ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-8729-0 ISBN 978-1-4939-8730-6 (eBook) https://doi.org/10.1007/978-1-4939-8730-6 Library of Congress Control Number: 2018951061 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Open Access Chapter 19 is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/). For further details see license information in the chapter. This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Humana Press imprint is published by the registered company Springer Science+Business Media, LLC part of Springer Nature. The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

Preface One can consider recombinant protein production in mammalian cells to be a mature technology. After all, the first commercial therapeutic recombinant proteins produced with mammalian cells were available to patients in the mid-1980s. Large-scale transient transfection of mammalian cells in suspension was developed in the mid-1990s, first with calcium phosphate as the DNA delivery vehicle followed by the cationic poly